{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T01:37:54Z","timestamp":1784079474525,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001259","name":"National Kidney Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["217316"],"award-info":[{"award-number":["217316"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.xkme.2026.101269","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:32:48Z","timestamp":1769099568000},"page":"101269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anemia Treatment and Its Clinical Implications in Patients Receiving Hemodialysis Hyporesponsive to Erythropoietin-Stimulating Agents"],"prefix":"10.1016","volume":"8","author":[{"given":"James B.","family":"Wetmore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Rouette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Requena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Gilbertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Wetten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiannong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.xkme.2026.101269_bib1","first-page":"279","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"10","key":"10.1016\/j.xkme.2026.101269_bib2","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.xkme.2026.101269_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100439","article-title":"Patient and care partner burden in CKD patients with and without anemia: a US-based survey","volume":"4","author":"Michalopoulos","year":"2022","journal-title":"Kidney Med"},{"issue":"5","key":"10.1016\/j.xkme.2026.101269_bib4","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1525-139X.2012.01089.x","article-title":"Red blood cell transfusion risks in patients with end-stage renal disease","volume":"25","author":"Tanhehco","year":"2012","journal-title":"Semin Dial"},{"issue":"5","key":"10.1016\/j.xkme.2026.101269_bib5","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/ndt\/gft053","article-title":"Global differences in dialysis modality mix: the role of patient characteristics, macroeconomics and renal service indicators","volume":"28","author":"van de Luijtgaarden","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.xkme.2026.101269_bib6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.xkme.2020.08.007","article-title":"Peritoneal dialysis in the United States: lessons for the future","volume":"2","author":"Hansson","year":"2020","journal-title":"Kidney Med"},{"key":"10.1016\/j.xkme.2026.101269_bib7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12882-015-0138-x","article-title":"Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients","volume":"16","author":"Sibbel","year":"2015","journal-title":"BMC Nephrol"},{"issue":"1-2","key":"10.1016\/j.xkme.2026.101269_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000528696","article-title":"Regional variation of erythropoiesis-stimulating agent hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D)","volume":"54","author":"Macdougall","year":"2023","journal-title":"Am J Nephrol"},{"issue":"12","key":"10.1016\/j.xkme.2026.101269_bib9","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.ekir.2023.09.009","article-title":"Contemporary practice of anemia treatment among dialysis patients in the United States","volume":"8","author":"Weinhandl","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"5","key":"10.1016\/j.xkme.2026.101269_bib10","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.xkme.2020.08.002","article-title":"Erythropoiesis-stimulating agent hyporesponsiveness and adverse outcomes: guilty as charged?","volume":"2","author":"Wish","year":"2020","journal-title":"Kidney Med"},{"issue":"4","key":"10.1016\/j.xkme.2026.101269_bib11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1440-1797.2007.00810.x","article-title":"Erythropoiesis-stimulating agent hyporesponsiveness","volume":"12","author":"Johnson","year":"2007","journal-title":"Nephrology (Carlton)"},{"issue":"25","key":"10.1016\/j.xkme.2026.101269_bib12","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1056\/NEJMoa2113379","article-title":"Daprodustat for the treatment of anemia in patients undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.xkme.2026.101269_bib13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.xkme.2020.06.008","article-title":"Clinical and economic outcome of erythropoiesis-stimulating agent hyporesponsiveness in the post-bundling era","volume":"2","author":"Cizman","year":"2020","journal-title":"Kidney Med"},{"issue":"5","key":"10.1016\/j.xkme.2026.101269_bib14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000523947","article-title":"Resistance to erythopoiesis-stimulating agents among patients on hemodialysis is typically transient","volume":"53","author":"Goodkin","year":"2022","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.xkme.2026.101269_bib15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000380972","article-title":"Erythropoiesis-stimulating agent hyporesponsiveness in end-stage renal disease patients","volume":"185","author":"Ogawa","year":"2015","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.xkme.2026.101269_bib16","unstructured":"Jha V, Claggett B, Bhatt N, et al. Daprodustat (dapro) dosing among prespecified subgroups including erythropoiesis-stimulating agent hyporesponders (ESA-HR) in dialysis-dependent patients (pts) in the ASCEND program. Abstract 220 presented at: National Kidney Foundation 2024 Spring Clinical Meetings; May 14-18, 2024; Long Beach, CA."},{"issue":"25","key":"10.1016\/j.xkme.2026.101269_bib17","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","article-title":"Daprodustat for the treatment of anemia in patients not undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.xkme.2026.101269_bib18","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.kint.2021.03.020","article-title":"Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference","volume":"99","author":"Babitt","year":"2021","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.xkme.2026.101269_bib19","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.kint.2023.05.009","article-title":"Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"104","author":"Ku","year":"2023","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.xkme.2026.101269_bib20","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/0091-7435(87)90049-1","article-title":"Racial difference in hemoglobin concentration of young adults","volume":"16","author":"Cresanta","year":"1987","journal-title":"Prev Med"},{"issue":"2","key":"10.1016\/j.xkme.2026.101269_bib21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.blre.2013.12.003","article-title":"The sex difference in haemoglobin levels in adults - mechanisms, causes, and consequences","volume":"28","author":"Murphy","year":"2014","journal-title":"Blood Rev"},{"key":"10.1016\/j.xkme.2026.101269_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f4822","article-title":"Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials","volume":"347","author":"Litton","year":"2013","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.xkme.2026.101269_bib23","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/01.tp.0000437435.19980.8f","article-title":"Red blood cell transfusions and the risk of allosensitization in patients awaiting primary kidney transplantation","volume":"97","author":"Leffell","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.xkme.2026.101269_bib24","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/1471-2369-14-200","article-title":"Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients","volume":"14","author":"Suttorp","year":"2013","journal-title":"BMC Nephrol"},{"issue":"5","key":"10.1016\/j.xkme.2026.101269_bib25","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2215\/CJN.06840712","article-title":"The USRDS: what you need to know about what it can and can't tell us about ESRD","volume":"8","author":"Foley","year":"2013","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526000300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526000300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:52:16Z","timestamp":1778907136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059526000300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2590059526000300"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101269","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anemia Treatment and Its Clinical Implications in Patients Receiving Hemodialysis Hyporesponsive to Erythropoietin-Stimulating Agents","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101269","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101269"}}